Analysis of patient satisfaction with a prefilled insulin injection device in patients with type 1 and type 2 diabetes.
ABSTRACT In this issue of Journal of Diabetes Science and Technology, Hancu and colleagues present an observational 6-8-week Pan-European and Canadian prospective survey on patient satisfaction with a prefilled insulin injection device, the SoloSTAR pen device, in patients with type 1 and 2 diabetes (n = 6542). The SoloSTAR pen is one of several up-to-date insulin pens of high quality and characteristics that fit many of our patients with diabetes. The mainly excellent-good votes of the participants for the SoloSTAR are not surprising, as we have seen continuous improvements with prefilled pens, such as the SoloSTAR device. Several years ago, patients as well as health care providers found considerable differences between the available pen options. Nowadays, as almost all pen providers have clearly improved their products, the differences are much smaller; we are closer to a "perfect" prefilled pen device. Nevertheless, there is a need for more randomized controlled trials, ideally sponsored not by just one manufacturer, to be able to make clear statements toward different pen device aspects (e.g., accuracy of dosing, adherence to therapy, ease of use, and patient satisfaction). An additional handicap is the difficulty to get blinded study designs.
Full-textDOI: · Available from: Thorsten Siegmund, Jul 07, 2014
SourceAvailable from: Devra K Dang[Show abstract] [Hide abstract]
ABSTRACT: Insulin therapy is a fundamental component of diabetes management, yet there is often resistance to insulin initiation by both prescribers and patients. A barrier to insulin use is the perceived shortcomings with the traditional vial-and-syringe administration method (inconvenience, difficulty of use, association with disease and addiction, etc.). This symposium in the journal discusses the advantages of alternative insulin delivery methods, primarily insulin pen devices. Although these administration methods, especially insulin pens, have some clear advantages over the vial/syringe, there are also limitations to their use and careful patient selection and education are still needed.Journal of diabetes science and technology 05/2010; 4(3):558-61. DOI:10.1177/193229681000400308
[Show abstract] [Hide abstract]
ABSTRACT: This study evaluated patient satisfaction with SoloSTAR® (sanofi-aventis), a prefilled insulin pen device for injection of insulin glargine or insulin glulisine. This was a 6-8-week multicenter (n = 652), observational, prospective Pan-European and Canadian registry study in patients with diabetes mellitus (n = 6542) who recently switched to or started treatment with insulin glargine and/or insulin glulisine using SoloSTAR or were insulin naïve. At the baseline visit, patients were asked to evaluate their satisfaction with their previous device, if applicable. After 6-8 weeks of SoloSTAR use, patients were asked to rate their satisfaction. Overall, 6481 patients (mean age 54 years, 48.7% male, 72% type 2 diabetes) were analyzed in this study. Of these, 4995 (77.1%) patients had used insulin before the study and 1641 (32.9%) and 3395 (68.0%) patients had previously used prefilled and/or reusable pens, respectively. During the study, SoloSTAR was used to administer insulin glargine and/or insulin glulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). Most patients rated SoloSTAR as "excellent/good" for ease of use (97.9%), learning to use (98.3%), selecting the dose (97.6%), and reading the dose (95.1%). Most patients rated ease of use (88.4%) and injecting a dose (84.5%) with SoloSTAR as "much easier/easier" versus their previous pen. Overall, 98% planned to continue using SoloSTAR. No safety concerns were reported. This European and Canadian survey shows that SoloSTAR was well accepted in this large patient population. Most patients preferred SoloSTAR to their previous pen and planned to continue SoloSTAR use.Journal of diabetes science and technology 09/2011; 5(5):1224-34. DOI:10.1177/193229681100500531
[Show abstract] [Hide abstract]
ABSTRACT: Insulin therapy is crucial to the treatment of many patients with diabetes mellitus. Therefore, it is important for pharmacists to consider the clinical and economic implications of the decision between insulin pens and insulin vials and syringes. Clinically, insulin pens show an advantage through improved adherence and reduced hypoglycemic events. Furthermore, overall health care costs were either unchanged or improved in insulin pen users as compared with those using insulin vials and syringes, although little economic advantage was observed when switching from insulin vials to insulin pens. Patients tend to prefer insulin pen use based on patient satisfaction and ease of use. Through an understanding of the advantages and disadvantages of insulin pens and vials and syringes, pharmacists can help to advocate for the most appropriate insulin-delivery method to maximize clinical outcomes and to reduce overall health care spending.The Consultant pharmacist: the journal of the American Society of Consultant Pharmacists 06/2011; 26(6):426-9. DOI:10.4140/TCP.n.2011.426